A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
Pharmacogenetics and Genomics2008Vol. 18(2), pp. 99–107
Citations Over TimeTop 1% of 2008 papers
Christine Lonjou, Nicolas Borot, Peggy Sekula, Neil Ledger, Laure Thomas, Sima Halevy, Luigi Naldi, Jan-Nico Bouwes-Bavinck, Alexis Sidoroff, Claudia de Toma, Martin Schumacher, Jean‐Claude Roujeau, Alain Hovnanian, Maja Mockenhaupt
Abstract
At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Related Papers
- → Toxic epidermal necrolysis: a paradigm of critical illness(2017)34 cited
- → Stevens-Johnson syndrome and toxic epidermal necrolysis(2017)19 cited
- → Pattern and impact of drug-induced liver injury in South African patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and a high burden of HIV(2021)4 cited
- → A Case Study of Toxic Epidermal Necrolysis(2019)1 cited
- → Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Nevirapine among HIV-Infected Pregnant Women: Five Cases(2017)